PALM BEACH GARDENS, Florida--As treatment protocols get more advanced and dental implants are placed in more challenging clinical scenarios, a surface that potentially provides a greater rate and extent of osseointegration on a more predictable basis, could be a benefit.
PALM BEACH GARDENS, Florida--As treatment protocols get more advanced and dental implants are placed in more challenging clinical scenarios, a surface that potentially provides a greater rate and extent of osseointegration on a more predictable basis, could be a benefit.
The NanoTite Implant starts with the industry-proven OSSEOTITE Surface at the core. Next, discrete nanometer scale crystals of calcium phosphate are deposited onto the OSSEOTITE Surface substrate. These crystals are bonded to the substrate, occupying approximately 50% of the surface, thereby being differentiated from the traditional plasma-sprayed CaP coatings that have been in commercial use for more than 20 years.
The NanoTite Implant starts with the industry-proven OSSEOTITE Surface at the core. Next, discrete nanometer scale crystals of calcium phosphate are deposited onto the OSSEOTITE Surface substrate. These crystals are bonded to the substrate, occupying approximately 50% of the surface, thereby being differentiated from the traditional plasma-sprayed CaP coatings that have been in commercial use for more than 20 years.
The nanoscale topography and potential biologic benefits associated with the CaP crystals may play a key role in enhanced site response, potentially improving clinical predictability and outcomes.
The nanoscale topography and potential biologic benefits associated with the CaP crystals may play a key role in enhanced site response, potentially improving clinical predictability and outcomes.
Preclinical studies demonstrate a substantial improvement on the rate and extent of osseointegration for the NanoTite Implant versus the OSSEOTITE Implant. Human histology has also demonstrated a marked increase in Bone-To-Implant Contact for the NanoTite Implant as compared to OSSEOTITE Implant Controls.
Preclinical studies demonstrate a substantial improvement on the rate and extent of osseointegration for the NanoTite Implant versus the OSSEOTITE Implant. Human histology has also demonstrated a marked increase in Bone-To-Implant Contact for the NanoTite Implant as compared to OSSEOTITE Implant Controls.
The result is potentially improved bone fixation, which may lead to greater stability for the implant during the critical early healing phases. This may improve predictability in more challenging clinical cases, to include poor bone quality, immediate and/or accelerated loading, short implants, wide diameter implants, simultaneous grafted sites, extraction sockets and aesthetic cases where bone preservation may be critical.
The result is potentially improved bone fixation, which may lead to greater stability for the implant during the critical early healing phases. This may improve predictability in more challenging clinical cases, to include poor bone quality, immediate and/or accelerated loading, short implants, wide diameter implants, simultaneous grafted sites, extraction sockets and aesthetic cases where bone preservation may be critical.
This new implant is available in two configurations: The NanoTite Certain Implant is a modified hybrid where the coverage of both the OSSEOTITE Surface and the nano-scale crystals go up to the base of the implant collar and the NanoTite PREVAIL Implant, which incorporates integrated Platform Switching and has the OSSEOTITE Surface and the nano-scale crystals to the top of the collar, creating a continuous bone-loading surface.
This new implant is available in two configurations: The NanoTite Certain Implant is a modified hybrid where the coverage of both the OSSEOTITE Surface and the nano-scale crystals go up to the base of the implant collar and the NanoTite PREVAIL Implant, which incorporates integrated Platform Switching and has the OSSEOTITE Surface and the nano-scale crystals to the top of the collar, creating a continuous bone-loading surface.
BIOMET 3i is a leading manufacturer of dental implants, abutments and related products. Since its inception in 1987, the company has been at the forefront in developing, manufacturing and distributing oral reconstructive products, including dental implant components and bone and tissue regenerative materials.
BIOMET 3i is a leading manufacturer of dental implants, abutments and related products. Since its inception in 1987, the company has been at the forefront in developing, manufacturing and distributing oral reconstructive products, including dental implant components and bone and tissue regenerative materials.
BIOMET 3i also provides educational programs and seminars for dental professionals around the world. The company is based in Palm Beach Gardens with operations throughout North America, Latin America, Europe and the Pacific Rim.
BIOMET 3i also provides educational programs and seminars for dental professionals around the world. The company is based in Palm Beach Gardens with operations throughout North America, Latin America, Europe and the Pacific Rim.
For more information, call (800) 443-8166 or 561-776-6700, or visit the company's Web site at www.biomet3i-online.com.
For more information, call (800) 443-8166 or 561-776-6700, or visit the company's Web site at www.biomet3i-online.com.
